Application of labeled trastuzumab to diagnose breast cancer in HER2 positive cases
Phase 2
- Conditions
- Metastatic breast cancer.Malignant neoplasm of breast
- Registration Number
- IRCT20180818040823N2
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 22
Inclusion Criteria
Patient with metastatic breast cancer and HER2 receptor
stage 4
No previous treatment with Herceptin
Negative estrogen and progesterone receptors
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ptake of radiopharmaceutical in lesions. Timepoint: At imaging time (60 minutes after injection). Method of measurement: Observation and semi-quantification using SUV.
- Secondary Outcome Measures
Name Time Method